| Synonyms: | |
| Status: | Phase 1 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | LDJ89SS0YG |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| BINDING AGENT | B-lymphocyte antigen CD20 binding agent |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Lymphoma, Follicular | 4 | D008224 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 3 | D008228 | ClinicalTrials |
| Lymphoma, B-Cell, Marginal Zone | 2 | D018442 | ClinicalTrials |
| Lymphoma, Large B-Cell, Diffuse | 2 | D016403 | ClinicalTrials |
| Lymphoma, B-Cell, Marginal Zone | 2 | D018442 | ClinicalTrials |
| Lymphoma, B-Cell | 1 | D016393 | ClinicalTrials |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | D015451 | ClinicalTrials |
| Leukemia, Biphenotypic, Acute | 1 | D015456 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1905409-39-3 |
| ChEMBL | CHEMBL4297788 |
| FDA SRS | LDJ89SS0YG |
CONTENTS